Navigation Links
Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods

LA JOLLA, Calif., May 7, 2012 /PRNewswire/ -- Zenobia Therapeutics, Inc. (Zenobia), the leader in fragment-based lead discovery (FBLD) for CNS diseases and FBLD/structural biology services, and BioBlocks, Inc. (BioBlocks), a leader in medicinal chemistry services and novel building block products, announced today that they are adding a 284 compound fragment library to their product offerings.  The library, ZB-Fragment Library 2, is ready for screening by all popular methods, contains soluble, verified protein binders, is shape and functionally diverse, and has an average molecular weight of 161.4 Da. The library was constructed by combining BioBlocks' unique expertise in medicinal chemistry and scaffold design with Zenobia's expertise in FBLD. Vicki Nienaber, Ph.D., President, CSO and founder of Zenobia, reported the first fragment-based crystallographic screening method (Nature Biotechnology 2000) and Robert Meadows, Ph.D. co-founder of Zenobia is an inventor of the SARbyNMR method (Science 1996). Industry veteran BioBlocks medicinal chemists have advanced numerous leads into preclinical and clinical development and have created a lead discovery platform capable of generating high quality patentable leads in a cost and time efficient manner.    

"Our customers have experienced an impressive success-rate in identifying valuable hits with Zenobia Fragment Library 1 with many returning to purchase additional copies. Establishing a collaborative relationship with BioBlocks allows us to jointly provide Fragment Library 2 with added core diversity and medicinal chemistry readiness using BioBlocks' unique expertise in creating leads from its building blocks," said Dr. Nienaber.  BioBlocks CEO, Dr. Pallai, said, "BioBlocks' core strength is the medicinal chemistry we utilize in collaborative drug discovery programs with our clients. Working with Zenobia allows us to take advantage of their unparalleled capabilities and experience in FBDD and SBDD and combine it with our expertise in fast fragment evolution, lead identification and optimizing compounds for pharmaceutical use. Our collaborative Fragment Library 2 provides a high quality starting point to generate lead compounds. With optimization, the final compounds are significantly more likely to occupy the high probability region of drug space than those developed from a typical HTS hit."   

Like Library 1, Library 2 is a small, cherry picked selection of diverse chemotypes and shapes, selected for manageable flexibility and compact interactions with target sites. Fragment functional groups are selected for their medicinal chemistry readiness and pharmaceutical appeal. There is no overlap between Library 1 and Library 2 so screening both will provide a wider variety of initial hits. The compounds are all soluble (200mM in DMSO), so screening with different methods is straightforward.

Through consulting or collaborations, Zenobia and BioBlocks offer structural biology, FBLD and medicinal chemistry expertise in advancing SAR around fragment hits.  

About Zenobia

Zenobia provides a commercial fragment library, and access to their structural biology, crystallography and fragment-based lead discovery expertise through partnerships, consulting and collaborations. Zenobia's internal programs combine fragment-based lead discovery with the expertise of biologists and clinicians to find treatments for devastating illnesses for which there is no disease altering treatment such as Parkinson's and Huntington's disease.

About BioBlocks

BioBlocks provides medicinal chemistry expertise to clients in the drug discovery community. In our collaborative projects we optimize partner's hits to leads and preclinical candidates. Our Leap-to-Lead platform addresses fundamental issues in drug discovery – the high attrition rate and lack of novelty found in typical HTS hits - by providing an alternative source for high quality tractable leads with multiple possible optimization pathways.  

For additional information on BioBlocks, Inc., contact Dr. Peter Pallai at or visit For additional information on Library 2 please contact or Zenobia, please see below.

For additional information on Zenobia Therapeutics, Inc., contact Dr. Vicki Nienaber at or visit For additional information on Zenobia's Fragment Library 1 or 2, contact Erika Zehm at

SOURCE Zenobia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Cell Therapeutics, Inc. (CTI) to Host Conference Call April 19, 8:30 AM ET
3. Nile Therapeutics, Inc. Completes $1.34 Million Registered Direct Offering
4. Nile Therapeutics, Inc. to Raise $1.4 Million in Registered Direct Offering
5. Echo Therapeutics, Inc. Announces 2011 Financial Results
6. Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones
7. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2011 Financial Results on March 7
8. Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
9. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
10. Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO Investor Forum
11. Womens Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):